Shalby Ltd Q1 FY27 Earnings Analysis

- Long-term sustainable growth expected at a minimum 15% CAGR in hospital and pharma business with existing infrastructure supporting 40%-50% upside (Page 13). - Expansion plans include selective hospital bed additions and MedTech product approvals in new countries like Myanmar and Vietnam, enhancing both hospital and MedTech growth (Page 16). - Commercial expansion ongoing across India, US, Japan, Southeast Asia, with new markets including Vietnam, Malaysia, Nepal, Iraq, Argentina, and LatAm regions targeted (Page 5). - Oncology and specialty services investments expected to contribute to revenue growth (Pages 11, 14). - Increased doctor additions and new therapies to start contributing from Q1/Q2 FY’27, strengthening revenue base (Page 14). - MedTech implant business projected to reach INR 600-700 crores revenue by 2030 with double-digit EBITDA (Page 13).

- **Revenue Growth**: Expecting sustainable minimum 15% CAGR over the long term driven by hospital and pharma business with existing infrastructure supporting 40-50% upsides. - **EBITDA**: Improvement anticipated from ongoing strategic measures such as doctor recruitment, specialty expansions, capex investments (robotics, oncology bunkers), and government scheme rate revisions. - **Profitability**: Significant improvement seen with standalone PAT margin at 23.3% in Q4 FY’26; recurring benefit from lower tax rate (25% vs earlier 35%). - **International Business**: Recovering from U.S.-Iran conflict impact, with growth in African and CIS markets; MedTech business showing positive EBITDA and working towards double-digit margins. - **Capex**: Heavy investment (~INR160 crores in FY’26), with limited capex planned for FY’27 supporting growth without significant cash outflow. - **EPS & PAT**: PAT substantially improved in FY’26 (INR34.7 crores vs INR1.9 crores in FY’25), expecting continued profitability gains.

- FY’26 capex was approximately INR 160 crores, focused largely on LINAC bunkers in Surat and Krishna units, oncology/radiation, robotics, PET CT, and related technological advancements. - Recent investments include heavy spend on oncology infrastructure (onco bunkers), robotics, radiation bunkers, and super specialty doctors recruitment. - Future capex in FY’27 is expected to be lower as heavy investment was done in FY’26. - Expansion plans include selective hospital bed additions meeting quality standards, and entering new MedTech markets such as Myanmar and Vietnam pending product approvals. - Focus on scaling MedTech business globally with continued innovation, regulatory groundwork, and manufacturing capacity. - Strategic investments also include strengthening franchisee models cautiously and growing international presence, including regulatory approvals in multiple markets like Southeast Asia, Latin America. - Continued investment in clinical education, accreditation (e.g., NABH in Gurugram), and platform technology like robotics with Curexo partnership for expansion. Overall, capex will be more selective and aligned with profitable growth and technological edge.

- There is no indication of any significant new fundraising through debt in the near term. - Borrowings in recent years were mainly due to two acquisitions (in the U.S. and Gurugram). - The company expects debt-to-equity ratio to remain healthy and improve over time. - The MedTech business has reached breakeven internationally, reducing urgency for more borrowings. - Recent quarters saw an equity infusion of approx. INR 60 crores into international hospital increasing equity share from ~87% to 91%. - Future capex spending is anticipated to be lower than FY'26 (INR 160 crores), suggesting limited need for immediate large fundraising. - Overall, focus is on improving cash flows and profitability rather than raising new funds.

The transcript of Shalby Limited's Q4 FY’26 earnings call does not explicitly mention the current or expected order book or pending orders. However, key insights related to business growth and demand include: - Continued exploration of profitable expansion opportunities both in hospitals and MedTech across markets like Myanmar, Vietnam, Vietnam, Malaysia, Nepal, Iraq, Argentina, and LatAm regions. - Positive momentum in international business despite geopolitical challenges (e.g., U.S.-Iran conflict), with growing patient inflows from CIS countries and Africa. - Strong confidence in growth driven by new product approvals and expansion in knee and hip implant categories. - Focus on strengthening surgeon networks and clinical partnerships to drive long-term demand. - Investments in oncology, robotics, and advanced therapies are expected to drive revenue and order inflows. - Robust growth plans in implant business targeting INR600-700 crores by 2030 with steady double-digit EBITDA. No direct mention of order book values or pending order backlog was provided.